Novo is "pleased" with the 23% weight loss that CagriSema caused, which shows that it offers "clinically meaningful additive weight loss effects" that are superior to what's been seen with drugs that only target GLP-1, Chief Scientific Officer Martin Holst Lange said in a release on Monday
The $99 genetic test analyzes variants in GLP1R, MC4R, FTO, and GIPR genes to reveal how your body responds to semaglutide across 14 metabolic pathways
This convenient nasal spray format allows for efficient delivery in controlled research environments, making it an ideal choice for laboratories investigating sleep architecture, circadian rhythms, and hormonal modulation
Published research on GHK-Cu has linked it to tissue remodeling, collagen synthesis, fibroblast support, anti-inflammatory activity, and broader regenerative signaling